Nitric oxide boosts chemoimmunotherapy via inhibition of acid sphingomyelinase in a mouse model of melanoma

Cancer Research

Volumn 67, Issue 16, 2007, Pages 7559-7564

  Perrotta, Cristiana ^a   Bizzozero, Laura ^d   Falcone, Sestina ^d   Rovere Querini, Patrizia ^a   Prinetti, Alessandro ^c   Schuchman, Edward H ^e   Sonnino, Sandro ^c   Manfredi, Angelo A ^a,b   Clementi, Emilio ^c,d  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d SCIENTIFIC INSTITUTE   (Italy)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; CISPLATIN; DENDRITIC CELL VACCINE; ISOSORBIDE DINITRATE; NITRIC OXIDE; SPHINGOMYELIN PHOSPHODIESTERASE;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CANCER TRANSPLANTATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DRUG SYNERGISM; ENZYME ACTIVATION; FEMALE; IMMUNOTHERAPY, ADOPTIVE; ISOSORBIDE DINITRATE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NITRIC OXIDE DONORS; NITROSO COMPOUNDS; SPHINGOMYELIN PHOSPHODIESTERASE;

EID: 34548052207     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0309     Document Type: Article

References (27)

1. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296-306.
2. Srivastava PK. Therapeutic cancer vaccines. Curr Opin Immunol 2006;18:201-5.
3. Steinman RM, Mellman I. Immunotherapy: bewitched, bothered, and bewildered no more. Science 2004;305:197-200.
4. Wijermans PW, Gerrits WB, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 1993;50:292-6.
5. Paolucci C, Rovere P, De Nadai C, Manfredi AA, Clementi E. Nitric oxide inhibits the tumor necrosis factor α-regulated endocytosis of human dendritic cells in a cyclic GMP-dependent way. J Biol Chem 2000;275:19638-44.
6. Paolucci C, Burastero SE, Rovere-Querini P, et al. Synergism of nitric oxide and maturation signals on human dendritic cells occurs through a cyclic GMP-dependent pathway. J Leukoc Biol 2003;73:253-62.
7. Shimamura H, Cumberland R, Hiroishi K, et al. Murine dendritic cell-induced tumor apoptosis is partially mediated by nitric oxide. J Immunother 2002;25:226-34.
8. Perrotta C, Falcone S, Capobianco A, et al. Nitric oxide confers therapeutic activity to dendritic cells in a mouse model of melanoma. Cancer Res 2004;64:3767-71.
9. Falcone S, Perrotta C, De Palma C, et al. Activation of acid sphingomyelinase and its inhibition by the nitric oxide/cyclic guanosine 3′,5′-monophosphate pathway: key events in Escherichia coli -elicited apoptosis of dendritic cells. J Immunol 2004;173:4452-63.
10. Kester M, Kolesnick R. Sphingolipids as therapeutics. Pharmacol Res 2003;47:365-71.
11. Lacour S, Hammann A, Grazide S, et al. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res 2004;64:3593-8.
12. Clementi E, Brown GC, Feelisch M, Moncada S. Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci U S A 1998;95:7631-6.
13. Wink DA, Vodovotz Y, Cook JA, et al. The role of nitric oxide chemistry in cancer treatment. Biochemistry Mosc 1998;63:802-9.
14. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006;6:521-34.
15. Markman M. Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf 2003;2:597-607.
16. Horinouchi K, Erlich S, Perl DP, et al. Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease. Nat Genet 1995;10:288-93.
17. Bulotta S, Barsacchi R, Rotiroti D, Borgese N, Clementi E. Activation of the endothelial nitric-oxide synthase by tumor necrosis factor-α. A novel feedback mechanism regulating cell death. J Biol Chem 2001;276:6529-36.
18. Liebmann J, DeLuca AM, Coffin D, et al. In vivo radiation protection by nitric oxide modulation. Cancer Res 1994;54:3365-8.
19. Turchi JJ. Nitric oxide and cisplatin resistance: NO easy answers. Proc Natl Acad Sci U S A 2006;103:4337-8.
20. Bratasz A, Weir NM, Parinandi NL, et al. Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. Proc Natl Acad Sci U S A 2006;103:3914-9.
21. Chanvorachote P, Nimmannit U, Stehlik C, et al. Nitric oxide regulates cell sensitivity to cisplatininduced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination. Cancer Res 2006;66:6353-60.
22. Konovalova NP, Goncharova SA, Volkova LM, Rajewskaya TA, Eremenko LT, Korolev AM. Nitric oxide donor increases the efficiency of cytostatic therapy and retards the development of drug resistance. Nitric Oxide 2003;8:59-64.
23. Azizzadeh B, Yip HT, Blackwell KE, et al. Nitric oxide improves cisplatin cytotoxicity in head and neck squamous cell carcinoma. Laryngoscope 2001;111:1896-900.
24. Prinetti A, Millimaggi D, D'Ascenzo S, et al. Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells. Biochem J 2006;395:311-8.
25. Sangro B, Melero I, Qian C, Prieto J. Gene therapy of cancer based on interleukin 12. Curr Gene Ther 2005;5:573-81.
26. Sciorati C, Galvez BG, Brunelli S, et al. Ex vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in muscular dystrophy. J Cell Sci 2006;119:5114-23.
27. Leventhal AR, Chen W, Tall AR, Tabas I. Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux. J Biol Chem 2001;276:44976-83.